Partnerships
Partnerships
Ready From Day One
We are uniquely positioned to address the challenges of targeted genetic medicine delivery with our partners. By combining expertise and infrastructure across viral drug delivery, manufacturing and clinical development, Vyriad is built from the ground up to innovate and translate meaningful therapies, and to partner with gene therapy developers for the highest chance of success in the clinic. We leverage interdisciplinary expertise along with a collaborative end-to-end approach to tailor the development of each viral delivery solution to our partners’ unique needs.
Building on a legacy of partnership
Vyriad partners with leading medical institutions and pharmaceutical companies to advance the development of gene therapies and oncolytic virotherapies. To develop Voyager-V1, our lead vesicular stomatitis virus (VSV)-based oncolytic virotherapy, we forged a long-standing and extensive research collaboration with Regeneron Pharmaceuticals. In 2019 Vyriad and Regeneron established a broad-based strategic agreement to discover and develop new oncolytic virotherapies that leverage Vyriad’s VSV platform, as well as Regeneron’s unmatched antibody discovery capabilities. Now, we are building upon our legacy of successful partnerships to develop targeted viral delivery solutions with partners that are helping to make in vivo therapies possible.
Key Partners in Our Science
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Vyriad and Regeneron have entered into a strategic research collaboration that includes a Phase 2 study of Voyager-V1 and Regeneron’s PD-1 inhibitor Libtayo® (cemiplimab-rwlc) in multiple cancer indications. We have also joined forces to design and develop novel vesicular stomatitis virus (VSV)-based oncolytic virotherapies.
Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, whole-person care to everyone who needs healing. Vyriad and Mayo Clinic have clinical research agreements to study Voyager-V1 across multiple cancer indications, both as a monotherapy and in combination with other immunotherapies.
Imanis Life Sciences is a virus engineering contract research organization based in Rochester, Minnesota. The company vision is to accelerate progress in regenerative medicine. Imanis Life Sciences provides clinical assays and research services and collaborates closely with Vyriad on virus engineering and characterization.
Interested in Partnering With Vyriad?
Vyriad works closely with researchers and clinicians at major pharmaceutical companies, leading universities, government institutions, and medical research centers around the world. Researchers interested in a preclinical or clinical collaboration with Vyriad are encouraged to contact us.